Abstract: Objective: This study aims to observe the efficacies and adverse reactions of modified vitamin programs before pemetrexed chemotherapy (second-line treatment) against epidermal growth factor receptor (EGFR) mutant wild-type lung adenocarcinoma. Methods: 477 patients with IIIB, phase IV glomerular filtration rate (GFR) mutantnegative lung adenocarcinomas and performed pemetrexed chemotherapy were collected and divided into group A (167 cases, with modified program) and group B (310 cases, with traditional program). The modified program was: orally administrated 400 μg folic acid once per day and 1 day before the first-round pemetrexed chemotherapy, until the 21st day of the final administration of pemetrexed, and intramuscularly injected 500 μg vitamin B12 1 day before the first-round pemetrexed chemotherapy, and injected once 1 day before every round pemetrexed treatment. Results: Comparison between group A and group B: mean chemotherapy cycles (4.08 vs 3.98); effectiveness rate (22.16% vs 22.90%); disease control rate (56.51% vs 55.00%); without significant difference (P > 0.05). Two groups currently all reached the median overall survival (OS). The median progression-free survival (PFS): 4.2 vs 4.1 months; OS: 12.9 vs 13.2 months, without statistical difference (P > 0.05). Such side effects between the two groups as leukopenia, neutropenia, thrombocytopenia, anemia, nausea, vomiting, diarrhea, fatigue, creatinine increasing, alanine transaminase (ALT) increasing, stomatitis, peripheral neuropathy, alopecia and rash had no significant difference (P > 0.05). Conclusions: The modified vitamin supportive treatment could ensure the efficacy, significantly simplify, facilitate the clinical application, and increase the associated toxicities, indicating that the pemetrexed-based chemotherapy did not need to be delayed because applying the vitamin supportive treatment.
Introduction
Lung cancer was one of the most common malignancies in world nowadays [1] , non-small cell lung cancer (NSCLC), especially adenocarcinoma, was the main type of lung cancer [2] . Nowadays, chemotherapy was the first treatment choice for NSCLC, while pemetrexed was mainly used as the second-line drug [3] [4] [5] , and also could be chosen as maintenance or firstline therapy as monotherapy or combined with cisplatin for advanced NSCLC [6] [7] [8] , even better efficacies and safeties than gemcitabine against non-squamous non-small cell lung cancer [9, 10] .
Pemetrexed was a new generation based on the classic anti-metabolic drug, which increased therapeutic effect on multiple enzymes in the folate-dependent metabolic pathways, including inhibit the activities of thymidylate synthase, dihydrofolate reductase and glycinamide nucleoside formyl transferase, reducing the biosynthesis of purine and thymidine, thus specifically affecting the folic acid synthesis of tumor cells, and inhibiting the proliferation of tumor cells [11] . Folic acid, as well as vitamin B12 were both needed before and during the chemotherapy course to reduce the toxicity of pemetrexed, now the traditional vitamin supplement program would normally refer to the previous clinical trials [12] , which would delay the treatment (before) or mislead the total dose of B12 (during). Based on our accumulated clinical experience of pemetrexed chemotherapy, we explored whether the vitamin supplement programs and courses could be simplified. In the present study, we retrospectively analyzed the application programs of vitamin supportive therapy before the pemetrexed chemotherapy against the patients with epidermal growth factor receptor (EGFR) wild-type lung adenocarcinoma, including the simplification and improvements of application period and doses, aiming to find out the its impacts on efficacies and related adverse reactions of pemetrexed chemotherapy.
Materials and methods

Inclusion criteria and clinical data
Inclusion criteria: (1) Pathologically/cytologically diagnosed, during the initial diagnosis, as the local advanced metastatic adenocarcinoma (IIIB or IV), could not perform the radical surgery, with negative EGFR mutation, failed or cardiogram (ECG). (8) With good compliance and signed the informed consent of chemotherapy, and willing to accept the follow-up. Exclusion criteria: (1) Allergic to the contrast agent or with hyperthyroidism; (2) with brain metastases; (3) with acute infection; (4) with severe heart, lung, liver and kidney dysfunctions, could not tolerate the chemotherapy; (5) appeared intolerable toxic reactions.
Object
According to the inclusion and exclusion criteria, 477 patients were selected from Sep. 2009 to Mar. 2014, including 237 males and 240 females, aged 26 to 83 years old, with the median age as 62 years old; among who 172 cases were in clinical phase IIIB, and 305 cases were in phase IV. The group A (167 patients) was performed the modified program (35.01%), while the group B was performed the traditional program (310 cases, 64.99%). Before the treatment, the comparison in sex, age, smoking, clinical phase, ECOG score, proportion of accepting treatment after first-line and secondline chemotherapy had no significant difference (P > 0.05, Table 1 ). This study was conducted in accordance with the declaration of Helsinki. This study was conducted with approval from the Ethics Committee of Guangzhou Medical University. Written informed consent was obtained from all participants. 
Hepatonephric functions: ALT ≤ 2-time normal upper limit, bilirubin ≤ normal upper limit, creatinine ≤ normal upper limit. (7) With normal electro-
Treatment
The group A, modified program: pemetrexed 500 mg/m 2 (Lilly France, Fegersheim, France), d1, intravenous infusion; vitamin B12 500 μg/ once (Norht China Pharmaceutical Company. Ltd, Hebei, China), intramuscular injection, one day before the chemotherapy, then once 1 day before the next cycle; folic acid 400 μg/d (Changzhou Pharmaceutical Factory Co., Ltd, Changzhou, China), oral administration, 1 day before the chemotherapy, until the 21st day after the chemotherapy, dexamethasone tablets 4 mg (Sinopharm Xingsha Pharmaceuticals Co. Ltd, Fujian, China), orally administrated 1 day prior to the chemotherapy, the exact day and the 2nd day after the chemotherapy, twice a day; the group B, traditional program: pemetrexed 500 mg/m 2 , d1, intravenous infusion; vitamin B12 1000 μg/once, intramuscular injection, seven days before the chemotherapy, once every three weeks; folic acid, 400 μg/d, oral administration, seven days before the chemotherapy, until the 21st day after the chemotherapy, dexamethasone tablets 4mg (orally administrated 1 day prior to the chemotherapy, the exact day and the 2nd day after the chemotherapy), twice a day. The two groups all set 21 days as one cycle. Before and after the treatment, the routine blood examination, hepatonephric functions and ECG were examined, if WC < 3.5×10 9 /L, the recombinant human granulocyte colony-stimulating factor was administrated for the support. If the degree III toxicity occurred, the dose should be reduced by 25%, and the chemotherapy should be postponed if degree IV toxicity occurred, and stopped for two consecutive degree IV toxic responses. the efficacies and toxicities were evaluated every two cycles. All patients were routinely applied the gastric mucosa-protective and antiemetic drugs.
Efficacy
Short-term efficacy evaluation was divided into complete response (CR), partial response (PR), patients. The second-line progression-free survival (PFS) referred to the time from the first application of second-line drug to PD. The overall survival (OS) referred to the time from diagnosis to death with any cause. The toxicity was classified by the chemotherapy toxicity standards of NCI CTC (version 3.0) and graded as level 0~IV.
Adverse reactions
I: mild reaction, no treatment; II: moderate reactions, in need of treatment; III: severe reactions, life-threatening, but recoverable; IV: severe reactions, lethal or promote death.
Statistical analysis
The SPSS16.0 software was used for the statistical analysis, the classification of variables used the χ 2 test to compare the basic situations and side effects of chemotherapy. The continuous variables were performed the T test. The analysis towards the toxicity predictors used the multivariate logistic regression. The median survival period was estimated with the KaplanMeier method, the survival curves were compared with the log-rank test, with P < 0.05 considered as the statistical significance.
Results
Basic information
The basic information of the 2 groups was shown in Table 1 . A total of 477 patients were enrolled, while there were no significant difference in basic information between the two groups.
Chemotherapy program and vitamin supplementary program
The two groups were both applied the pemetrexed alone chemotherapy, and applied 4 mg dexamethasone on the exact day and one day before and after the chemotherapy, respective- stable disease (SD) and progressive disease (PD) according to the RECIST criteria. The overall response rate (ORR) was CR+PR. The objective response rate (ORR) was the ratio of (CR+PR) to the total patients. Disease control rate (DCR) was the ratio (CR+PR+SD) to the total ly, as well as the bis in die (BID) anti-allergy treatment; 8 mg ondansetron was intravenously infused to prevent such side effects as vomiting, etc. The pemetrexed dosage of one round in both 2 groups was 500 mg/m 2 . The patients of the two groups completed a total of 1917-round chemotherapy, among which the group A completed 681 rounds, and the group B completed 1236 rounds. The numbers of chemotherapy rounds towards each patient ranged from 2-10 rounds. There 13 and 23 patients in group A and group B, respectively, that occurred phase III-IV myelosuppression thus reduced the dosage (1.90% vs 1.86%, P = 0.913); the average chemotherapy round was (4.08 vs 3.98, P = 0.692), the pemetrexed dosages between the 2 groups had no statistical difference (average 492 mg/m 2 vs 489 mg/m 2 per round, P = 0.778, Table 2 ).
Side effects
Chemotherapy-associated side effects with the two groups were shown in Table 3 . The side effects of the chemotherapy within both groups were mild, and showed no statistically significant difference in overall toxicities in non-blood cally used, the incidence rates of nausea and vomiting between the 2 groups were low, 22.75% vs 22.26%, P = 0.875; the incidence rates of anemia, thrombocytopenia, serum creatinine increasing, alanine transaminase (ALT/ GPT) increasing, stomatitis, diarrhea, infections, peripheral neuropathy, hair loss and skin rashes showed no significant difference between the 2 groups.
Efficacy evaluation
The follow-up was lasted until July 2014. The effectiveness rates of the A and B group were (22.16% vs 22.90%, P = 0.825); the disease control rate was: (56.89% vs 56.77%, P = 0.981), showing no significant difference as shown in Table 4 . All patients were in the stage of second-line progress when the data were being collected. And there were only 137 patients that were still alive, the patients of the two groups all had reached the median OS. The median PFS of the A and B group were 4.2 months and 4.1 months, showing no significant difference (P = 0.272, Figure 1A) . OS of the two groups were 12.9 months and 13.2 months, showing no significant difference (P = 0.099, Figure 1B ).
Discussion
Pemetrexed was multi-target antagonist of folic acid, and the first chemotherapeutic drug with specific targets with low toxicities [13, 14] , since folic acid was necessary in the synthesis and transformation of purine nucleic acid and and blood systems. Leukopenia and neutrophil deficiency were the most common adverse effects observed within the two groups. The results found that there was no significant difference in such side effects as leukopenia (19.76% vs 20.97%, P = 0.813) and neutrophil deficiency (2.40% vs 2.26%, P = 0.924) between the 2 groups.
As for the non-hematologic toxicities, fatigue was still the most common adverse reaction, 31.14% vs 30.97%, P = 0.804; because the antiemetics was routinely prophylacti-pyrimidine nucleotides, the supplements was indispensable during any chemotherapy with antagonist of folic acid [15] , and vitamin B12, which involved in the manufacture of marrow erythrocyte, was also need to be supplied exogenously [16] .
Folic acid played an important role towards the cell growth, as well as the synthesis of nucleic acids, amino acids and proteins. When folic acid exhibited the deficiency, megaloblastic anemia, neutropenia and thrombocytopenia might be induced, and such gastrointestinal symptoms as appetite loss, bloating, diarrhea and glossitis might also be caused, the folic acid deficiency could cause hyperhomocysteinemia, thus increasing the risks of cardiovascular diseases. Vitamin B12 was indirectly involved in the synthesis of thymidine nucleotide. When Vitamin B12 was deficient, its impacts on the hematology were similar to folic acid, namely the DNA synthesis would be blocked, thus leading to the megaloblastic anemia.
After intramuscularly injected 1 mg vitamin B12, its plasma concentration could be maintained above 1 ηg/ml for 2.1 months. The metabolic characteristics of vitamin B12 absorbent might be the reason that vitamin B12 should be intramuscularly injected once every three chemotherapy rounds (63 days) in the traditional schemes. It would be 14 days for the metabolite level to recover from the supplement of folic acid and vitamin B12, so the traditional programs would perform vitamin supportive therapy 1-2 weeks before the pemetrexed chemotherapy [17] .
Several previous studies [18] [19] [20] [21] [22] demonstrated that the patients with vitamin supportive therapy suffered from less side effects of pemetrexed chemotherapy, thus the vitamin supportive therapy was necessary to reduce the pemetrexed-related side effects. However, the specific timing of vitamin supportive therapy during the pemetrexed chemotherapy had no concrete evidence-based medical proofs. Yang et al [23] found that high doses of folic acid and vitamin B12 had no effect towards the anticancer efficacies of pemetrexed, while it might increase the sensitivities of tumor cells towards pemetrexed, the NSCLC patient with vitamin B12 supportive therapy exhibited better survival rates after the pemetrexed therapy. Though the traditional programs deemed it to be necessary that the vitamin supportive therapy should be applied 7 days before the first dose of pemetrexed, Griffin found in a retrospective analysis that the timing of vitamin treatment of 8 NSCLC patients (mainly adenocarcinoma) was less than five days before the pemetrexed chemotherapy, and no major adverse events occurred [24] . Socinski et al [25] found in one retrospective analysis towards the Phase II clinical experimental study of pemetrexed in treating the recurrent small cell lung cancer that the application timing of vitamin B12 (less than 7 days before the first dose of pemetrexed) did not increase serious side effects, and there was no correlation between the application timing of vitamin B12 before the first dose of pemetrexed and the side effects. Kim et al. [26] enrolled a total 350 NSCLS patients from Nov 2009 to April 2012 into the pemetrexed chemotherapy, the patients were divided into two groups (the experimental group had 56 patients, and there was no significant difference in the basic information between the 2 groups), the 2 groups were performed the vitamin supportive therapy at different timings before the first cycle of pemetrexed chemotherapy (5-14 d vs 4 d or less). The effectiveness rates, PFS and the side effects in the first cycle of chemotherapy showed no statistical significance. These studies indicated that vitamin supportive therapy before the pemetrexed therapy might not require 1-2 weeks. Even as for the patients without vitamin deficiency, the vitamin supportive therapy one week before the chemotherapy treatment could be seen as the unnecessary delay towards the chemotherapy, and it prolonged the patients' hospital stay and increased the hospital costs. The previous studies were mainly the retrospective analysis, and the sample sizes were small, the optimized fixation time of vitamin support before the pemetrexed therapy was not clarified.
This study made up the shortcomings of previous analytical researches to some extent, significantly simplified and clarified the specific dose and timing of vitamin applications, namely the intramuscular injection of 500 μg vitamin B12 could only be a day before the chemotherapy, followed one injection towards every round; 400 μg/d folic acid could be orally administrated one day before the chemotherapy, until the 21st day after the final round of chemotherapy; this method was much more convenient than the traditional program, and would not be difficult to be missed. Of course, whether our supportive program was the best option still needed to be proved by more clinical practice and experiments.
In short, our modified simplified vitamin programs could not only ensure the effects of second-line pemetrexed chemotherapy, but also significantly simplify and facilitate the clinical application, and no side effects were increased. Especially in the first round, the vitamins application did not need to be 7 days before the chemotherapy, thus it could avoid that the best treatment time was delayed because of the vitamin supplementary therapy, so it was worthy of further study.
